olivier blin
olivier blin
prof marseille
Verified email at ap-hm.fr
TitleCited byYear
Nonmotor fluctuations in Parkinson’s disease: frequent and disabling
T Witjas, E Kaphan, JP Azulay, O Blin, M Ceccaldi, J Pouget, M Poncet, ...
Neurology 59 (3), 408-413, 2002
6212002
Quantitative analysis of gait in Parkinson patients: increased variability of stride length
O Blin, AM Ferrandez, G Serratrice
Journal of the neurological sciences 98 (1), 91-97, 1990
3941990
Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease
O Blin, AM Ferrandez, J Pailhous, G Serratrice
Journal of the neurological sciences 103 (1), 51-54, 1991
3771991
Visual control of locomotion in Parkinson's disease
JP Azulay, S Mesure, B Amblard, O Blin, I Sangla, J Pouget
Brain 122 (1), 111-120, 1999
3701999
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
CM Beasley, SH Hamilton, AM Crawford, MA Dellva, GD Tollefson, ...
European Neuropsychopharmacology 7 (2), 125-137, 1997
3621997
Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti‐GM1 antibodies: a double‐blind, placebo‐controlled study
JP Azulay, O Blin, J Pouget, J Boucraut, F Bille-Turc, G Carles, ...
Neurology 44 (3 Part 1), 429-429, 1994
2961994
Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study
RA Emsley, Risperidone Working Group
Schizophrenia Bulletin 25 (4), 721-729, 1999
2371999
Peyro Saint Paul H, Azulay JP, et al: Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson’s disease and multiple system atrophy
O Blin, C Desnuelle, O Rascol, M Borg
J Neurol Sci 125, 95-101, 1994
161*1994
Dopaminergic contribution to the regulation of emotional perception
P Salgado-Pineda, P Delaveau, O Blin, A Nieoullon
Clinical neuropharmacology 28 (5), 228, 2005
1502005
Influence of visual cues on gait in Parkinson's disease: contribution to attention or sensory dependence?
JP Azulay, S Mesure, O Blin
Journal of the neurological sciences 248 (1-2), 192-195, 2006
1442006
A comparative review of new antipsychotics
O Blin
Canadian journal of psychiatry 44, 235-244, 1999
1441999
Neural bases of different cognitive strategies for facial affect processing in schizophrenia
E Fakra, P Salgado-Pineda, P Delaveau, AR Hariri, O Blin
Schizophrenia research 100 (1-3), 191-205, 2008
1432008
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease
O Rascol, JG Nutt, O Blin, CG Goetz, JM Trugman, C Soubrouillard, ...
Archives of neurology 58 (2), 249-254, 2001
1392001
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients
O Blin, JM Azorin, P Bouhours
Journal of clinical psychopharmacology 16 (1), 38-44, 1996
1331996
Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double‐blind controlled study in general practice
N Nguyen, E Fakra, V Pradel, E Jouve, C Alquier, ME Le Guern, J Micallef, ...
Human Psychopharmacology: Clinical and Experimental 21 (3), 139-149, 2006
1292006
Dopaminergic modulation of visual sensitivity in man
G Masson, D Mestre, O Blin
Fundamental & clinical pharmacology 7 (8), 449-463, 2009
1252009
Long term follow up of multifocal motor neuropathy with conduction block under treatment.
JP Azulay, P Rihet, J Pouget, F Cador, O Blin, J Boucraut, G Serratrice
Journal of Neurology, Neurosurgery & Psychiatry 62 (4), 391-394, 1997
1241997
Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage
V Drago, C Babiloni, D Bartrés-Faz, A Caroli, B Bosch, T Hensch, M Didic, ...
Journal of Alzheimer's Disease 26 (s3), 159-199, 2011
1222011
Impact of a prescription monitoring program on doctor‐shopping for high dosage buprenorphine
V Pradel, E Frauger, X Thirion, E Ronfle, V Lapierre, A Masut, C Coudert, ...
Pharmacoepidemiology and drug safety 18 (1), 36-43, 2008
1182008
Effect of ascorbic acid in patients with Charcot–Marie–Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial
J Micallef, S Attarian, O Dubourg, PM Gonnaud, JY Hogrel, T Stojkovic, ...
The Lancet Neurology 8 (12), 1103-1110, 2009
1172009
The system can't perform the operation now. Try again later.
Articles 1–20